Granules India and Ajinomoto OmniChem create jv in India

Published: 18-Jul-2011
Manufacturing Ingredients Finance Pharmaceutical

Granules OmniChem will operate an API and intermediates facility in Vishakhapatnam, Andhra Pradesh

Belgian chemicals company Ajinomoto OmniChem and Indian pharmaceuticals manufacturer Granules India have formed a 50:50 joint venture to produce active pharmaceutical ingredients (APIs) and intermediates for third parties.

The new company, Granules-OmniChem, will build a US$20m plant in the Pharmacity SEZ zone in Vishakhapatnam, Andhra Pradesh, initially to manufacture high-value, low-volume APIs and intermediates.

Construction of the facility will start in November and should be completed towards the end of 2012.

The jv aims to capitalise on demand from pharmaceutical firms which are outsourcing their manufacturing needs at a time when the industry is focused on the US$234bn generics market. More than 80% of API production is for the generics market.

Granules-Omnichem will focus on producing APIs and intermediates for existing customers of both partners and in the future manufacture new chemical entities.

‘Our shareholders will benefit since this will enable Granules to diversify its business by offering high value APIs and intermediates which will increase our profitability,’ said Krishna Prasad, managing director of Granules.

Gwin Bompas, managing director of Ajinomoto OmniChem, which employs around 700 people at three sites in Belgium, said the jv would enable the firm to ‘offer access to quality medicine at an affordable price for the market’.

Granules India manufactures finished dosage forms, pharmaceutical intermediates and APIs, which are distributed in more than 50 countries.

See more

You may also like

Manufacturing

Ajinomoto Bio-Pharma Services buys out joint venture company

Read more
The purchase will transfer the remaining 50% ownership of Granules OmniChem from Ajinomoto’s joint venture partner, Granules India

Trending Articles

  1. Novo Nordisk launches the first oral GLP-1 in the US with new Wegovy pill The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    From pilots to production: what 2026 could mean for pharma This editorial examines predictions from the HSBC Innovation Banking Life Sciences and Healthcare team on how innovation, investment and consolidation are expected to shape the market in 2026
  3. Romaco Holding GmbH Romaco is a leading international supplier of machinery and integrated system solutions for the development, production and packaging of pharmaceuticals, nutraceuticals, food, cosmetic and chemical products. All from a single source.
  4. Ultra-high potency and its impact on pharmaceutical outsourcing This article explores the emerging distinction between high and ultra-high potency APIs, highlighting the implications for pharmaceutical outsourcing and risk management in an evolving therapeutic landscape
  5. Ajinomoto CELLiST Korea launches CELLiST AAV Production Supplement to enhance gene therapy manufacturing efficiency The new cell culture media supplement that has been shown to boost adeno-associated virus (AAV) vector productivity by up to two-fold, addressing a key bottleneck in scalable and cost-effective gene therapy manufacturing

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Manufacturing

Ajinomoto Bio-Pharma Services buys out joint venture company

The purchase will transfer the remaining 50% ownership of Granules OmniChem from Ajinomoto’s joint venture partner, Granules India
Finance

Indian Big Pharma companies buck the global economic trend

India\'s top 25 pharma companies continue to go from strength to strength
Manufacturing

Two decades of safe drying and storage solutions from SICCO

In the UK, Labtex supply the full spectrum of SICCO desiccators, drying cabinets and glove boxes for use in demanding industrial sectors
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Miniaturisation in medtech: mechanical factors that influence product success

Medical devices are becoming smaller, lighter and more portable. From handheld diagnostic tools to wearable infusion pumps and compact surgical instruments, reduced size is now a defining feature of many new medtech products
Manufacturing

MedPharm completes FDA inspection of manufacturing plant in Durham

The topical drug product manufacturing facility in North Carolina successfully completed its FDA inspection for the commercial manufacture of drug products with no Form 483 issued plus an NAI classification
Finance

European life sciences investors kick off 2026 with targeted bets on immunity, oncology and metabolic health

From thymus regeneration and ECM-targeted oncology to fast-scaling metabolic health technology, three European companies secure fresh capital as investors double down on differentiated science with clear commercial momentum
Manufacturing

Sharp Sterile Manufacturing invests $28m into US sterile fill-finish site

The investment will more than double the existing Massachusetts site's filling capacity, strengthening Sharp's long-term commitment to US-based sterile drug production
Subscribe now